Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 12/24/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Scott Siegel?

Scott A. Siegel

Founder and Chief Executive Officer

Milestone Life Sciences

Direct Phone: (908) ***-****direct phone

Email: s***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

C14 Consulting Group LLC


Executive-in-Residence (Part Time)

NYU


Senior Director, New Business Development

Ortho Biotech Products , L.P.


Co-Inventor

Remicade


Vice President of Corporate Development

Company News Redpoint Bio


Chief Operating Officer and Vice President, Business Development

Ezose Sciences Inc


Vice President of Corporate Development

Redpoint Bio Corporation


Vice President Business Development

Institute for Life Science Entrepreneurship


Adjunct Associate Professor of Microbiology

University of Pennsylvania


Affiliations

IIR Ltd

Member of Advisory Board


Education

Yale University School of Medicine


Bachelor of Science degree

biology

State University of New York , College at New Paltz


MBA

communications

Wharton School


Ph.D.

Biochemistry

SUNY


Ph.D.

biochemistry

State University of New York


Web References(52 Total References)


Scott A. Siegel, PhD | C14 Consulting

c14consultinggroup.com [cached]

Scott A. Siegel, PhD
Scott Siegel, PhD Scott A. Siegel, PhD Founder & CEO, Milestone Life Sciences Vice President, Business Development, Institute of Life Science Entrepreneurship Dr. Scott Siegel has a 25-year record of business and science achievements in biotech and pharma, including the execution of over 40 business development transactions and R&D development of three launched products, including as co-inventor of the blockbuster anti-TNF therapy Remicade®. His leadership experience ranges from start-ups to large multinationals, with a breadth of responsibilities spanning business, science, technologies and therapeutic areas. He founded and currently manages Milestone Life Sciences, a business development and strategic advisory firm to small biotech's and pharma. Dr. Siegel also serves as Vice President, Business Development for the newly formed non-profit Institute of Life Science Entrepreneurship, a NJ-based incubator, accelerator and aggregator, and he teaches a communications course in the Wharton School MBA program. Previously, he was COO and Vice President, Business Development for the start-up Ezose Sciences Inc., where he built and then led operations. Prior to that Dr. Siegel was VP, Corporate Development for Redpoint Bio Inc., a microcap public biotech with unique technology in taste science and diabetes. He spent eight years with Johnson & Johnson in new business development and worldwide strategic marketing, with responsibilities in scientific and commercial scouting, assessment, licensing and partnerships. His R&D roles included Senior Director, Preclinical R&D for the start-up Phytera, Inc.; Associate Director, Immunobiology for Centocor, Inc.; and Section Leader, Immunodiagnostics for Becton Dickinson and Co. He also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Technology Transfer. Dr. Siegel earned his PhD in Biochemistry from SUNY, Downstate Medical Center in Brooklyn, New York, and completed postdoctoral training in Pharmacology at the Yale University School of Medicine in New Haven, Connecticut.


ILSE Hosts NJ Bio Pharma Networking Group

ilsebio.com [cached]

• Scott Siegel, PhD, Managing Director, Milestone Life Sciences, LLC


SCOTT A. SIEGEL, PHD

ilsebio.com [cached]

SCOTT A. SIEGEL, PHD
SCOTT A. SIEGEL, PHD Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer. Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.


www.ilsebio.com

Scott A. Siegel, PhD
VP Business Development Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer. Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.


transpacifichsd.com

Scott A. Siegel, PhD, Managing Director, Milestone Life Sciences, LLC


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory